title: Proceedings of the Indo-U.S. bilateral workshop on accelerating botanicals/biologics agent development research for cancer chemoprevention, treatment, and survival.
abstract: With the evolving evidence of the promise of botanicals/biologics for cancer chemoprevention and treatment, an Indo-U.S. collaborative Workshop focusing on “Accelerating Botanicals Agent Development Research for Cancer Chemoprevention and Treatment” was conducted at the Moffitt Cancer Center, 29–31 May 2012. Funded by the Indo-U.S. Science and Technology Forum, a joint initiative of Governments of India and the United States of America and the Moffitt Cancer Center, the overall goals of this workshop were to enhance the knowledge (agents, molecular targets, biomarkers, approaches, target populations, regulatory standards, priorities, resources) of a multinational, multidisciplinary team of researcher's to systematically accelerate the design, to conduct a successful clinical trials to evaluate botanicals/biologics for cancer chemoprevention and treatment, and to achieve efficient translation of these discoveries into the standards for clinical practice that will ultimately impact cancer morbidity and mortality. Expert panelists were drawn from a diverse group of stakeholders, representing the leadership from the National Cancer Institute's Office of Cancer Complementary and Alternative Medicine (OCCAM), NCI Experimental Therapeutics (NExT), Food and Drug Administration, national scientific leadership from India, and a distinguished group of population, basic and clinical scientists from the two countries, including leaders in bioinformatics, social sciences, and biostatisticians. At the end of the workshop, we established four Indo-U.S. working research collaborative teams focused on identifying and prioritizing agents targeting four cancers that are of priority to both countries. Presented are some of the key proceedings and future goals discussed in the proceedings of this workshop.
authors.forename: Nagi B
authors.initials: NB
authors.lastname: Kumar
authors.forename: Medha
authors.initials: M
authors.lastname: Dhurandhar
authors.forename: Bharat
authors.initials: B
authors.lastname: Aggarwal
authors.forename: Shrikant
authors.initials: S
authors.lastname: Anant
authors.forename: Kenyon
authors.initials: K
authors.lastname: Daniel
authors.forename: Gary
authors.initials: G
authors.lastname: Deng
authors.forename: Julie
authors.initials: J
authors.lastname: Djeu
authors.forename: Jinhui
authors.initials: J
authors.lastname: Dou
authors.forename: Ernest
authors.initials: E
authors.lastname: Hawk
authors.forename: B
authors.initials: B
authors.lastname: Jayaram
authors.forename: Libin
authors.initials: L
authors.lastname: Jia
authors.forename: Rajendra
authors.initials: R
authors.lastname: Joshi
authors.forename: Madhuri
authors.initials: M
authors.lastname: Kararala
authors.forename: Devarajan
authors.initials: D
authors.lastname: Karunagaran
authors.forename: Omer
authors.initials: O
authors.lastname: Kucuk
authors.forename: Lalit
authors.initials: L
authors.lastname: Kumar
authors.forename: Mokenge
authors.initials: M
authors.lastname: Malafa
authors.forename: G J
authors.initials: GJ
authors.lastname: Samathanam
authors.forename: Fazlul
authors.initials: F
authors.lastname: Sarkar
authors.forename: Maqsood
authors.initials: M
authors.lastname: Siddiqi
authors.forename: Rana P
authors.initials: RP
authors.lastname: Singh
authors.forename: Anil
authors.initials: A
authors.lastname: Srivastava
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: White
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D035843:Biomedical Research / Q000379:methods; D018890:Chemoprevention / Q000379:methods; D055808:Drug Discovery / Q000379:methods* / Q000639:trends; D006801:Humans; D007391:International Cooperation; D009369:Neoplasms / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D001688:Biological Products